- The FDA's Circulatory System Devices Panel of the Medical Devices Advisory Committee voted 11-4 in favor of approval for Cardinal Health (NYSE:CAH) unit Cordis' INCRAFT AAA Stent Graft System for the treatment of infrarenal aortic aneurysms.
- The device was CE Mark'd in 2014.
- Previously: Ad Com June 12 for Cardinal's InCraft stent; shares ahead 6% (May 10)
FDA Ad Com backs Cardinal's Incraft stent
Recommended For You
About CAH Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
CAH | - | - |
Cardinal Health, Inc. |